Key Takeaways

  • Z Optics has received approval to expand its European Z+ Virtual Aperture IOL clinical trial into Canada

  • The investigational lens is designed to provide continuous near-to-distance vision while minimizing visual disturbances associated with multifocal IOLs

  • Canadian study sites will be announced as activated, with clinical results expected after data collection and analysis

Z Optics announced that its ongoing European clinical study evaluating the Z+ Virtual Aperture IOL has received approval to expand into Canada, allowing Canadian clinical sites to participate in the multicenter trial.

The expansion marks the first opportunity for Canadian patients to access the investigational lens through a clinical study.

The trial is evaluating the safety and performance of the Z+ Virtual Aperture IOL, which is designed to provide continuous vision across near, intermediate, and distance ranges under both daytime and nighttime lighting conditions.

Built on a monofocal platform, the lens uses a light-reshaping approach rather than splitting light, redirecting out-of-focus light away from the central retina. According to the company, the technology is intended to reduce halos, glare, and other visual disturbances associated with multifocal IOL designs.

Z Optics reported positive preliminary feedback from European investigators and patients since enrollment began. Investigators have described a broad depth of focus, favorable visual outcomes, and a surgical experience similar to standard monofocal IOL implantation. Quantitative clinical results have not yet been released.

“The response from patients and physicians in our European study has exceeded our expectations,” said Luke Clauson, CEO of Z Optics. “Extending the trial to Canada is an important step for the program. It broadens the clinical evidence base for the Virtual Aperture technology and, just as importantly, it means patients and surgeons in Canada can now experience this lens within the study.”

The company plans to announce participating Canadian clinical sites as they become activated. Clinical results are expected following completion of data collection and analysis, although a reporting timeline has not been specified.